Inhibiting TGF-β activity improves respiratory function in mdx mice.

  title={Inhibiting TGF-β activity improves respiratory function in mdx mice.},
  author={Carol A. Nelson and R. B. Hunter and Lindsay A Quigley and Stefan Girgenrath and William D. Weber and Jennifer A McCullough and Carol J Dinardo and Kelly A Keefe and Lorena Ceci and Nicholas P Clayton and Alison J. McVie-Wylie and Seng H. Cheng and John P. Leonard and B. M. Wentworth},
  journal={The American journal of pathology},
  volume={178 6},
Respiratory function is the main cause of mortality in patients with Duchenne muscular dystrophy (DMD). Elevated levels of TGF-β play a key role in the pathophysiology of DMD. To determine whether therapeutic attenuation of TGF-β signaling improves respiratory function, mdx mice were treated from 2 weeks of age to 2 months or 9 months of age with either 1D11 (a neutralizing antibody to all three isoforms of TGF-β), losartan (an angiotensin receptor antagonist), or a combination of the two… CONTINUE READING